附件99.1

Valneva宣布年度股东大会取得成功并任命两名新的监事会成员

圣赫布赖恩(法国)，2022年6月24日-特种疫苗公司Valneva SE(纳斯达克：VALN；泛欧交易所股票代码：VLA)今天宣布，昨天在巴黎举行的股东年度大会(AGM)上，董事会建议的所有决议都得到了股东的批准。

通过的决议包括批准2021年财务报表、授权管理委员会 增加Valneva的股本和/或发行金融工具，以及任命两名新的监事会成员，任期三年。

Bpifrance Participations被任命为Valneva监事会成员，将由Maílys Ferrère代表。 费雷尔女士是法国国有投资银行Bpifrance大型风险投资公司的董事总裁。 在Bpifrance担任董事期间，她是泛欧交易所上市公司的多个董事会成员。在2013年加入Bpifrance Large Venture之前，费雷尔女士是Fond Stratégique d‘InvestsDepartment的董事投资人。在此之前，Ferrère女士的职业是银行业，专注于各种金融机构的股权资本市场。她毕业于巴黎政治学院。

美国人詹姆斯·爱德华·康诺利也被任命为瓦尔内瓦监事会成员。康诺利先生是一位经验丰富的企业高管，在生命科学行业拥有30多年的经验。自2013年以来，康诺利先生一直在多家疫苗、生物制药和投资机构的董事会任职。2010至2013年，康诺利先生担任AERAS(现为IAVI)总裁兼首席执行官。在此之前，他在惠氏(现为辉瑞)有长达24年的成功职业生涯，在那里他担任了一系列高级职位，最后两个职位是惠氏疫苗执行副总裁兼总经理和惠氏加拿大公司总裁。在领导惠氏疫苗期间，康诺利发挥了领导作用，将该公司的疫苗业务 打造成全球四大制造商之一，并创造了第一个真正的重磅炸弹疫苗Prevnar，销售额超过30亿美元。

此外，监事会成员弗雷德里克·格里莫、詹姆斯·苏拉特和安妮·玛丽·格拉芬的任期延长至2025年6月。在另一次会议上，弗雷德里克·格里莫再次当选为Valneva监事会主席。

Valneva还在年度股东大会上证实，莱姆病候选疫苗VLA15 的第三阶段研究计划于2022年第三季度启动，预计将在2022年下半年向食品和药物管理局(FDA)提交其基孔肯雅候选疫苗VLA1553的生物制品许可证申请(BLA)。

年度股东大会的投票结果将在未来几天在Valneva公司网站的“投资者和媒体”部分公布。

关于Valneva SE
Valneva是一家专业疫苗公司，专注于针对重大医疗需求未得到满足的传染病的预防性疫苗的开发和商业化。该公司采取高度专业化和针对性的方法进行疫苗开发，然后应用其对疫苗科学的深刻理解来开发针对这些疾病的预防性疫苗 。Valneva利用其专业知识和能力成功地将两种疫苗商业化，并迅速将各种候选疫苗 推向临床并通过临床推广，包括莱姆病、基孔肯雅病毒和新冠肺炎的候选疫苗。

Valneva前瞻性陈述
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates and estimates for future performance. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.